17th Meet the Professor. Advanced International Breast Cancer Course
CORSO ECM: 4 crediti erogati
TITOLO: 17th Meet the Professor. Advanced International Breast Cancer Course
DATA: scade il 14/10/2022
Il corso FAD è disponibile al seguente indirizzo https://fad.accmed.org/
Dopo aver seguito le lezioni affronta il test finale e confronta con me le risposte esatte al seguente indirizzo Risposte
- The 2 most frequent somatic mutations within HER2-positive disease are the following:
- Adjuvant chemotherapy is most effective in the following group of patients:
- The most accurate method to predict chemotherapy benefit in primary invasive breast cancer is:
- For patients who present with clinically negative axillary nodes and receive neoadjuvant chemotherapy, which of the following statements regarding the performance characteristics of sentinel lymph node biopsy (SLNB) is correct?
- All of the following are considered high penetrance genes for developing breast cancer except:
- La risposta patologica completa dopo terapia neoadiuvante è:
- Nelle pazienti con carcinoma mammario a recettori ormonali positivi HER2 negativo metastatico:
- Avoidance of side effects after radiation therapy: Radiation therapy side effects need to be revisited because (mark what is not correct):
- Sacituzumab Govitecan (Trop-2-Directed ADC):
- One of the following molecular alterations is associated with higher response to chemotherapy within HER2+ disease:
- The median overall survival time of metastatic triple negative breast cancer (from the moment of relapse) in the chemotherapy era was of:
- Genomic prediction of radiation therapy benefits: Currently available predictive tests as used for systemic therapy can be used for radiation therapy as well:
- Il tumore mammario BRCA mutato è:
- Trastuzumab Deruxtecan is a
- Quale è per incidenza e prevalenza la neoplasia più frequente nella donna con obesità: